Latest News
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy
In the RESILIENT SMA study, Biohaven announced today that taldefgrobep alpha showed clinically meaningful improvements in motor function at all time points on the Motor Function Measurement-32 scale (MFM-32), but […]
Read More ›SMA Community Advocacy Wins and Champions Celebrated at Cure SMA Event
Individuals with spinal muscular atrophy (SMA) and their families recognized congressional champions and celebrated advocacy progress at Cure SMA’s Hope on the Hill event. U.S. Representative Sam Graves (MO-6) Photo: […]
Read More ›Celebrate 40 Years of Impact – Join Us in Making a Difference!
Thank you for being an essential part of this journey and for believing in our mission. As we mark 40 years of dedicated service to the spinal muscular atrophy (SMA) […]
Read More ›Spinal Muscular Atrophy (SMA) Update in Best Practices: Recommendations for Treatment Considerations
As part of our ongoing efforts to drive quality health care standardization and improvements for the SMA community, Cure SMA is pleased to announce the next publication in a series […]
Read More ›Make an Impact with Cure SMA’s Mission, Milestones, Momentum Campaign
We’re kicking off our Mission, Milestones, Momentum Year-End Campaign with an incredible $50,000 matching gift. In honor of Hunter Rhodes, living with SMA, the Johns Family has generously donated $50,000 […]
Read More ›Majority of Children with SMA Treated with Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before 6 weeks of age, with most achieving motor milestones similar to children without SMA All children were […]
Read More ›